$
1. 81
+0.07
+4.023%
$
20.15M Market Cap
- P/E Ratio
- Div Yield
1.08M Volume
- Eps
$ 1.74
Previous Close Investors:
Want to track SER and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce bloodstream infections up to 77% according to their Phase 1b trial. SER-155 also holds the FDA's Breakthrough and Fast Track designations. MCRB targets more interim Phase 2 SER‑155 data within 12 months.
Seekingalpha | 10 months ago
